期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 121, 期 9, 页码 3375-3383出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI57158
关键词
-
资金
- Deutsche Forschungsgemeinschaft, Bonn, Germany [SFB654, C5, C8, SFB841, C1, SFB877, A1, A2]
- Cluster of Excellence Inflammation at Interfaces
- Arthritis Research UK [18286, 19381, 18461]
- Wellcome Trust
- Arthritis Research UK Centre in Biomechanics and Bioengineering [18461]
- Versus Arthritis [19381] Funding Source: researchfish
The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the beta-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据